The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Grigorova O.V.

Serbsky National Medical Research Center for Psychiatry and Narcology, Moscow, Russia

Akhapkin R.V.

Gosudarstvennyĭ nauchnyĭ tsentr sotsial'noĭ i sudebnoĭ psikhiatrii im. V.P. Serbskogo, Moskva

Aleksandrovskiĭ Iu.A.

Modern concepts of pathogenetic therapy of anxiety disorders

Authors:

Grigorova O.V., Akhapkin R.V., Aleksandrovskiĭ Iu.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10): 111‑120

DOI: 10.17116/jnevro2019119101111

Read: 20885 times

Contact the author
Table of contents

MODERN CONCEPTS OF PATHOGENETIC THERAPY OF ANXIETY DISORDERS
MODERN CONCEPTS OF PATHOGENETIC THERAPY OF ANXIETY DISORDERS

To cite this article:

Grigorova OV, Akhapkin RV, Aleksandrovskiĭ IuA. Modern concepts of pathogenetic therapy of anxiety disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10):111‑120. (In Russ.)
https://doi.org/10.17116/jnevro2019119101111

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Psycho-emotional state and self-reported sleep quality in students with bimo­dality of the ability to be active in the morning and evening in the sleep—wake cycle. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):130-134
Effe­cts of sema­glutide on mental health. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):28-36
Basic and complex therapy of non-segmental viti­ligo with como­rbid anxiety and anxiety-depressive adju­stment diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):51-58
Resu­lts of the obse­rvational program CITO­TREK (use of the drug CITO­flavin in Tablets) in patients with tension headaches against the backgRound of asthenic syndromE taKing into account como­rbidity. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):104-112
Perceptions of the disease and self-assessment of the quality of life in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):24-31
Classification, diagnosis and therapy of atte­ntion defi­cit hype­ractivity diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):62-68
Conscious seda­tion with benzodiazepines in pediatric outpatient dentistry. Russian Journal of Anesthesiology and Reanimatology. 2025;(3):55-63
Dysfunctional pelvic pain in women. Russian Journal of Pain. 2025;(2):32-37
Effect of perioperative nore­pinephrine infu­sion on the outcomes after microsurgical free tissue grafting: a systematic review. Russian Journal of Anesthesiology and Reanimatology. 2025;(5):98-107
The role of substance P in modu­lation of inflammation and immune response: from neurotransmitter to therapeutic target. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(5):566-572
Abstract:

The high prevalence of anxiety disorders around the world leads to a high interest in the study of anxiety. At the moment, a lot of knowledge about the pathogenesis and therapy of anxiety disorders has been accumulated, which is well covered in modern domestic and world medical literature. It is known that many areas of the brain are involved in the modulation of anxiety, among which the amygdala is considered the key in the modulation of anxiety and fear. A large body of evidence supports the involvement of different neurotransmitter systems in the processes of anxiogenesis-anxiolysis (GABA, monoamines, glutamate, neuropeptides, neurosteroids). This article provides an analysis of methods of pharmacological impact on each of these systems, which serve to optimize the already known strategies of anxiolytic therapy.

Keywords:

anxiety
pathogenesis of anxiety disorders
neurobiology of anxiety disorders
therapy of anxiety disorders
anxiolytic drug
GABA
glutamate
neuropeptides
neurosteroids
monoamines
serotonin
dopamine
noradrenaline
histamine

Authors:

Grigorova O.V.

Serbsky National Medical Research Center for Psychiatry and Narcology, Moscow, Russia

Akhapkin R.V.

Gosudarstvennyĭ nauchnyĭ tsentr sotsial'noĭ i sudebnoĭ psikhiatrii im. V.P. Serbskogo, Moskva

Aleksandrovskiĭ Iu.A.

Close metadata

References:

  1. Aleksandrovsky YuA. Pre-morbid conditions and borderline mental disorders (etiology, pathogenesis, specific and nonspecific symptoms, therapy). M.: Litterra; 2010. (In Russ.)
  2. Regier DA, Narrow WE, Rae DS. The epidemiology of anxiety disorders: The Epidemiologic Catchment Area (ECA) experience. Journal of Psychiatric Research. 1990;24(suppl 2):3-14. https://doi.org/10.1016/0022-3956(90)90031-k
  3. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:718-779. https://doi.org/10.1016/j.euroneuro.2011.07.018
  4. Weiller E, Bisserbe JC, Maier W, Lecrubier Y. Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO study on Psychological Problems in General Health Care. Brithish Journal of Psychiatry. 1998;(suppl 34):18-23. https://doi.org/10.1192/s0007125000293471
  5. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry. 2005;62:593-602. https://doi.org/10.1001/archpsyc.62.6.593
  6. Aleksandrovsky YuA, Bardenshtein LM, Avedisova AS. Psychopharmacotherapy of borderline mental disorders. M.: Geotar Medicina; 2000. (In Russ.)
  7. Christmas D, Hood S, Nutt D. Potential Novel Anxiolytic Drugs. Current Pharmaceutical Design. 2008;14:3534-3546. https://doi.org/10.2174/138161208786848775
  8. Klein DF. Delineation of two drug responsive anxiety syndromes. Psychopharmacology. 1964;5(6):397-408. https://doi.org/10.1007/bf02193476
  9. Toth M. Neurobiology of anxiety. Handbook of contemporary neuropharmacology. Sibley D., Hanin I., Kuhar M., Skolnick P. Hoboken, New Jersey: John Wiley & Sons; 2007;2:3-57. https://doi.org/10.1002/9780470101001
  10. Gray JA, McNaughton N. The neuropsychology of anxiety: an enquiry into the functions of the septo-hippocampal system, 2nd ed. Oxford University Press, Oxford. 2000. https://doi.org/10.1093/acprof:oso/9780198522713.003.0010
  11. Engin E, Treit D. The anxiolytic-like effects of allopregnanolone vary as a function of intracerebral microinfusion site: the amygdala, medial prefrontal cortex, or hippocampus. Behav Pharmacol. 2007;18:461-470. https://doi.org/10.1097/fbp.0b013e3282d28f6f
  12. Perez de la Mora M, Jacobsen KX, Crespo-Ramirez M, Flores-Gracia C, Fuxe K. Wiring and volume transmission in rat amygdala. Implications for fear and anxiety. Neurochem Res. 2008;33:1618-1633. https://doi.org/10.1007/s11064-008-9722-9
  13. Pitkanen A, Stefanacci L, Farb CR, Go GG, LeDoux JE, Amaral DG. Intrinsic connections of the rat amygdaloid complex: projections originating in the lateral nucleus. J Comp Neurol. 1995;356:288-310. https://doi.org/10.1002/cne.903560211
  14. Price JL, Amaral DG. An autoradiographic study of the projections of the central nucleus of the monkey amygdala. J Neurosci. 1981;1:1242-1259. https://doi.org/10.1523/jneurosci.01-11-01242.1981
  15. Sun N, Cassel MD. Intrinsic GABAergic neurons in the rat central amygdala. J Comp Neurol. 1993;330:381-404. https://doi.org/10.1002/cne.903300308
  16. McDonald AJ. Glutamate and aspartate immunoreactive neurons of the rat basolateral amygdala: colocalization of excitatory amino acids and projections to the limbic circuit. J Comp Neurol. 1993;365:367-379. https://doi.org/10.1002/(sici)1096-9861(19960212)365:3<367::aid-cne3>3.3.co;2-i
  17. McDonald AJ. Is there an amygdala and how far does it extend? An anatomical perspective. Ann NY Acad Sci. 2003;985:1-21. https://doi.org/10.1111/j.1749-6632.2003.tb07067.x
  18. Davis M. The role of the amygdala in conditioned fear. In: Aggleton JP (Ed.). The amygdala: neurobiological aspects of emotion, memory and mental dysfunction. New York: Wiley-Liss, Inc.; 1992;255-305.
  19. Royer S, Martina M, Pare D. An inhibitory interface gates impulse traffic between the input and output stations of the amygdala. J Neurosci. 1999;19:10575-10583. https://doi.org/10.1523/jneurosci.19-23-10575.1999
  20. Sun N, Yi H, Cassell MD. Evidence for a GABAergic interface between cortical afferents and brainstem projection neurons in the rat central extended amygdala. J Comp Neurol. 1994;340:43-64. https://doi.org/10.1002/cne.903400105
  21. Marowsky A, Yanagawa Y, Obata K, Vogt KE. A specialized subclass of interneurons mediates dopaminergic facilitation of amygdala function. Neuron. 2005;48:1025-1037. https://doi.org/10.1016/j.neuron.2005.10.029
  22. McDonald AJ. Cortical pathways to the mammalian amygdala. Prog Neurobiol. 1998;55:257-332. https://doi.org/10.1016/s0301-0082(98)00003-3
  23. Royer S, Martina M, Pare D. Polarized synaptic interactions between intercalated neurons of the amygdala. J Neurophysiol. 2000;83:3509-3518. https://doi.org/10.1152/jn.2000.83.6.3509
  24. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol. 2003;70:83-244. https://doi.org/10.1016/s0301-0082(03)00087-x
  25. Lapin IP. In: Anxiety and obsessions. Ed. Smulevich A.B. M. 1998. (In Russ.)
  26. Aleksandrovsky YuA. Psychiatry and psychopharmacotherapy. Selected lectures and presentations. M.: GEOTAR-Med; 2004. (In Russ.)
  27. Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 2001;179:390-396. https://doi.org/10.1192/bjp.179.5.390
  28. Borodin VI. Side effects of tranquilizers and their role in borderline psychiatry. Psychiatry and Psychopharmacology. 2000;3:72-74. (In Russ.)
  29. Vein AM, Dyukova GM, Vorobieva OV, Danilov AB. Panic attacks. SPb.: OOO «Institute of medical marketing»; 1997. (In Russ.)
  30. Rickels K, Schweizer E, Case GC and Greenblatt DJ. Long-term therapeutic use of benzodiazepines: I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990;47:899-907.
  31. Whiting, PJ. GABA-A receptors: a viable target for novel anxiolytics? Current Opinion in Pharmacology. 2006;6(1):24-29. https://doi.org/10.1016/j.coph.2005.08.005
  32. Rudolph U, Mohler H. Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu Rev Pharmacol Toxicol. 2004;44:475-498. https://doi.org/10.1146/annurev.pharmtox.44.101802.121429
  33. Aleksandrovsky YuA, Romasenko LV, Krasnov VN i dr. Efficiency Etifoxine in comparison with the Phenazepam in the treatment of patients with adaptation disorders (open-label randomized controlled study). Novosti Mediciny i Farmacii. 2010;17:10-11. (In Russ.)
  34. Frank van B, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacology (Berl). 2003;165(2):97-110. https://doi.org/10.1007/s00213-002-1257-1
  35. Zwanzger P, Eser D, Padberg F, Baghai TC, Schule C, Rötzer F, Ella R, Möller HJ, Rupprecht R. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress Anxiety. 2003;18:140-143. https://doi.org/10.1002/da.10099
  36. Dunlop BW, Papp L, Garlow SJ, Weiss PS, Knight BT, Ninan PT. Tiagabine for social anxiety disorder. Hum Psychopharmacol. 2007;22:241-244. https://doi.org/10.1002/hup.846
  37. Syunyakov TS, Syunyakov SA, Morozov PV. Review of the effectiveness of pregabalin in generalized anxiety disorder from the position of its spectral characteristics. Psychiatry and Psychopharmacotherapy. 2013;15:1:94-100. (In Russ.)
  38. Van den Heuvel OA, Veltman DJ, Groenewegen HJ, Witter MP, Merkelbach J, Cath DC, van Balkom AJLM, van Oppen P, van Dyck R. Disorder-specific neuroanatomical correlates of attentional bias in obsessive-compulsive disorder, panic disorder, and hypochondriasis. Arch Gen Psychiatry. 2005;62:922-933. https://doi.org/10.1001/archpsyc.62.8.922
  39. Rauch SL, Shin LM, Wright CI. Neuroimaging studies of amygdala function in anxiety disorders. Ann NY Acad Sci. 2003;985:389-410. https://doi.org/10.1111/j.1749-6632.2003.tb07096.x
  40. Bergink V, van Megen HJ, Westenberg HG Glutamate and anxiety. Eur Neuropsychopharmacol. 2004;14:175-183. https://doi.org/10.1016/s0924-977x(03)00100-7
  41. Shigemoto R, Kinoshita A, Wada E, Nomura S, Ohishi H, Takada M, Flor PJ, Neki A, Abe T, Nakanishi S, and Mizuno N. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci. 1997;17(19):7503-7522. https://doi.org/10.1523/jneurosci.17-19-07503.1997
  42. Plaznik A, Palejko W, Nazar M and Jessa M. Effects of Antagonists at the NMDA Receptor Complex in Two Models of Anxiety. European Neuropsychopharmacology. 1994;4(4):503-512. https://doi.org/10.1016/0924-977x(94)90299-2
  43. Kotlinska J, Liljequist S. A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701,324. Psychopharmacology. 1998;135(2):175-181. https://doi.org/10.1007/s002130050499
  44. Grigorova OV, Romasenko LV, Vazagaeva TI, Maksimova LN, Narcissov YaR. Efficacy of anxiety therapy in patients with adaptation disorder on the model of glycine therapy with placebo-reactivity. Rossiiskii Psikhiatricheskii Zhurnal = Russian Journal of Psychiatry. 2012;4:45-52. (In Russ.)
  45. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008;63:544-549. https://doi.org/10.1016/j.biopsych.2007.11.011
  46. Alt A, Weiss B, Ogden AM, Li X, Gleason SD, Calligaro DO, Bleakman D, Witkin JM. In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders. Psychopharmacology. 2006;185(2):240-247. https://doi.org/10.1007/s00213-005-0292-0
  47. Varty GB, Grilli M, Forlani A, Fredduzzi S, Grzelak ME, Guthrie DH, Hodgson RA, Lu SX, Nicolussi E, Pond AJ, Parker EM, Hunter JC, Higgins GA, Reggiani A, Bertorelli R. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology (Berl). 2005;179:207-217. https://doi.org/10.1007/s00213-005-2143-4
  48. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tolleson GD. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology. 2008;33:1603-1610. https://doi.org/10.1038/sj.npp.1301531
  49. Turner JP, Salt TE. Group II and III metabotropic glutamate receptors and the control of the nucleus reticularis thalami input to rat thalamocortical neurones in vitro. Neuroscience. 2003;122(2):459-469. https://doi.org/10.1016/j.neuroscience.2003.08.014
  50. Ressler KJ. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. In: Ressler KJ, Nemeroff C. Depress Anxiety. 2000;12(suppl 1):2-19. https://doi.org/10.1002/1520-6394(2000)12:1+<2::aid-da2>3.3.co;2-w
  51. Schank JR, Liles LC, Weinshenker D. Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety. Biol Psychiatry. 2008;63(11):1007-1012. https://doi.org/10.1016/j.biopsych.2007.10.018
  52. Maes M, Van Gastel A, Delmeire L, Kenis G, Bosmans E, Song C. Platelet alpha2-adrenoceptor density in humans: relationships to stress-induced anxiety, psychasthenic constitution, gender and stress-induced changes in the inflammatory response system. Psychol Med. 2002;32(5):919-928. https://doi.org/10.1017/s0033291702005925
  53. Nutt DJ. Increased central alpha 2-adrenoceptor sensitivity in panic disorder. Psychopharmacology (Berl). 1986;90(2):268-269. https://doi.org/10.1007/bf00181255
  54. Akimova E, Lanzenberger R, Kasper S. The serotonin-1A receptor in anxiety disorders. Biol Psychiatry. 2009;66:627-635. https://doi.org/10.1016/j.biopsych.2009.03.012
  55. Donaldson ZR, Piel DA, Santos TL, Richardson-Jones J, Leonardo ED, Beck SG, Champagne FA, Hen R. Developmental effects of serotonin-1A autoreceptors on anxiety and social behavior. Neuropsychopharmacology. 2014;39:291-302. https://doi.org/10.1038/npp.2013.185
  56. Mosolov SN. Biological methods of therapy of mental disorders (evidence — based medicine-clinical practice). In ed.: Mosolov S.N. M.: BINOM; 2012. (In Russ.)
  57. Hood SD, Bell CJ, Nutt DJ. Acute tryptophan depletion. Part I: rationale and methodology. Aust N Z J Psychiatry. 2005;39(7):558-564. https://doi.org/10.1111/j.1440-1614.2005.01627.x
  58. Schruers K, Griez E. The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder. J Psychopharmacol. 2004;18(4):553-558. https://doi.org/10.1177/0269881104047283
  59. Charney DS, Woods SW, Goodman WK, Heninger GR. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl). 1987;92(1):14-24. https://doi.org/10.1007/bf00215473
  60. Blier P, de Montignyc C, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry. 1990;51(suppl):14-20; discussion 21: 14-20.
  61. Ferres-Coy A, Santana N, Castane A, Cortes R, Carmona MC, Toth M, Montefeltro A, Artigas F, Bortolozzi A. Acute 5-HT(1A) autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions. Psychopharmacology (Berl). 2013;225:61-74. https://doi.org/10.1007/s00213-012-2795-9
  62. Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol. 2001;4:399-408. https://doi.org/10.1017/s1461145701002632
  63. Deakin JFW, Graeff FG. 5-HT and mechanisms of defense. J Psychopharmacol. 1991;5:305-315. https://doi.org/10.1177/026988119100500414
  64. Johnson PL, Lightman SL, Lowry CA. A functional subset of serotonergic neurons in the rat ventrolateral periaqueductal gray implicated in the inhibition of sympathoexcitation and panic. Ann NY Acad Sci. 2004;1018:58-64. https://doi.org/10.1196/annals.1296.006
  65. Eser D, Baghai TC, Moller HJ. Evidence of agomelatine’s antidepressant efficacy: the key points. Int Clin Psychopharmacol. 2007;22(suppl 2):15-19. https://doi.org/10.1097/01.yic.0000277958.83475.d5
  66. Audero E, Mlinar B, Baccini G, Skachokova ZK, Corradetti R, Gross C. Suppression of serotonin neuron firing increases aggression in mice. J Neurosci. 2013;33:8678-8688. https://doi.org/10.1523/jneurosci.2067-12.2013
  67. Nash JR, Sargent PA, Rabiner EA, Hood SD, Argyropoulos SV, Potokar JP, Grasby PM, Nutt DJ. A positron emission tomography study of serotonin 5-HT1A receptor availability in untreated and recovered patients with panic disorder. Br J Psychiatry. 2008;193:1-6. https://doi.org/10.1192/bjp.bp.107.041186
  68. Eison. The new generation of serotonergic anxiolytics: possible clinical roles. Psychopathology. 1989;22(suppl 1):13-20. https://doi.org/10.1159/000284622
  69. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. CNS Agents Med Chem. 2009;9:197-204. https://doi.org/10.2174/1871524910909030197
  70. Avedisova AS, Akhapkin RV. Efficacy and tolerability of Afobazole therapy (results of open multicenter naturalistic program). Russian Medical Journal. 2007;4:259. (In Russ.)
  71. Seredenin SB, Voronin MV. Neuroreceptor mechanisms of action of afobazole. Experimental and Clinical Pharmacology. 2009;72(1):3-11. (In Russ.)
  72. Suliman S, Hemmings SMJ, Seedat S. Brain-Derived Neurotrophic Factor (BDNF) protein levels in anxiety disorders: systematic review and meta-regression analysis. Frontiers in Integrative Neurosci. 2013;7:55. https://doi.org/10.3389/fnint.2013.00055
  73. Gudasheva TA, Povarnina PYu, Seredenin SB. Dipeptidyl a mimetic of brain-derived neurotrophic factor prevents the violation of neurogenesis in stressed mice. Bull Exper Biol i Med. 2016;162(10):448-451. (In Russ.)
  74. Benc C, Bonord A, Rebillar C, Vaast P, Alexandre C, Rolland B, Jardri R. Neonatal abstinence syndrome following tianeptine dependence during pregnancy. Pediatrics. 2016;137(1):1-4. https://doi.org/10.1542/peds.2015-1414
  75. Fuxe K, Canals M, Torvinen M, Marcellino D, Terasmaa A, Genedani S, Leo G, Guidolin D, Diaz-Cabiale Z, Rivera A, Lundstrom L, Langel U, Narvaez J, Tanganelli S, Lluis C, Ferreґ S, Woods A, Franco R, Agnati LF. Intramembrane receptor—receptor interactions: a novel principle in molecular medicine. J Neural Transm. 2007;114:49-75. https://doi.org/10.1007/s00702-006-0589-0
  76. Barishpolec VV. New analogs of dopamine: axiotron action and hormonal status. Psychopharmacology and Biological Narcology. 2008;8(1-2):2354. (In Russ.)
  77. Hantouche EG, Ferreri M. Effectiveness of the gidroxizina with generalized anxiety. Psychiatry and Psychopharmacotherapy. 2000;2(4):124-125.
  78. Alvarez EO. The role of histamine on cognition. Behavioural Brain Research. 2009;199(2):183-189. https://doi.org/10.1016/j.bbr.2008.12.010
  79. Kost NV, Meshavkin VK, Zozulya AA. Neuropeptides in the regulation of anxiety. Psychiatry. 2010;4:64-75. (In Russ.)
  80. Ashmarin IP, Stukalova PV, Eshchenko ND. Biochemistry of the Brain. SPb.: Izd-vo SPb un-ta; 1999. (In Russ.)
  81. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. Journal of Psychiatry and Neuroscience. 2006;22(5):332. https://doi.org/10.1016/s0924-977x(01)80436-3
  82. Ebner K, Rupniak NM, Saria A, Singewald N. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci USA. 2004;101:4280-4285. https://doi.org/10.1073/pnas.0400794101
  83. Michelgard A, Appel L, Pissiota A, Frans O, Langstrom B, Bergstrom M, Fredrikson M. Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol Psychiatry. 2007;61:1002-1006. https://doi.org/10.1016/j.biopsych.2006.07.003
  84. Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry. 2005;58:132-142. https://doi.org/10.1016/j.biopsych.2005.03.029
  85. Eckart K, Jahn O, Radulovic J, Radulovic M, Blank T, Stiedl O, Brauns O, Spiess J. Pharmacology and biology of corticotropin-releasing factor (CRF) receptors. Receptors and Channels. 2002;8(3-4):163-177. https://doi.org/10.1080/10606820213678
  86. Smith GW, Aubry J-M, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W, Lee K-F. Corticotropin releasing factor receptor. 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron. 1998;20:1093-1102. https://doi.org/10.1016/s0896-6273(00)80491-2
  87. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, Chrousos GP, McCann SM, Suomi SJ, Higley JD, Gold PW. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA. 2000;97:6079-6084. https://doi.org/10.1073/pnas.97.11.6079
  88. Primeaux SD, Wilson SP, Cusick MC, York DA, Wilson MA. Effects of altered amygdalar neuropeptide Y expression on anxiety-related behaviors. Neuropsychopharmacology. 2005;30(9):1589-1597. https://doi.org/10.1038/sj.npp.1300705
  89. Heilig M, Thorsell A. Brain neuropeptide Y (NPY) system: a candidate target for treatment of anxiety, depression and alcohol dependence. Rev Neurosci. 2002;13:85-94. https://doi.org/10.1358/dof.2004.029.02.850944
  90. Kask A, Harro J, von Hörsten S, Redrobe P, Dumont Y, Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Biobehav Rev. 2002;26:259-283. https://doi.org/10.1016/s0149-7634(01)00066-5
  91. Sajdyk T, Vandergriff MG, Gehlert DR. Amygdalar neuropeptide Y Y-1 receptors mediate the anxiolytic actions of neuropeptide Y in the social interaction test. Eur J Pharmacol. 1999;368:143-147. https://doi.org/10.1016/s0014-2999(99)00018-7
  92. Janecka A, Fichna J, Janecki T. Opioid receptors and their ligands. Curr Top Med Chem. 2004;4:1-17. https://doi.org/10.2174/1568026043451618
  93. Megarbane B, Gueye P, Baud F. Interactions between benzodiazepines and opioids. Ann Med Interne (Paris). 2003;154 (2):64-72.
  94. Comings D, Dietz G, Gade-Andavolu R, Blake H, Muhleman D, Huss M, Saucier G, MacMurray J. Association of neutral endopeptidase (MME) gene with anxiety. Psychiatr Genet. 2000;20(2):91-94. https://doi.org/10.1097/00041444-200010020-00007
  95. Olsson M, Annerbrink K, Westberg L, Melke J, Baghaei F, Rosmond R, Holm G, Andersch S, Allgulander C, Eriksson E. Angiotensin-related genes in patients with panic disorder. Am J Med Genet B Neuropsychiatr Genet. 2004;127(1):81-84. https://doi.org/10.1002/ajmg.b.20164
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.